重组人血管内皮抑素(恩度)联合化疗治疗晚期大肠癌的近期疗效及毒副反应观察.docVIP

重组人血管内皮抑素(恩度）联合化疗治疗晚期大肠癌20例分析 闻杨1，董洪敏1，张红丽，王文玲1，王刚1 （1．贵州省贵阳医学院附属肿瘤医院 肿瘤科，贵州省 贵阳市 550000） 【关键词】重组人血管内皮抑素／恩度；晚期大肠癌； 靶向治疗； 化疗 ；近期疗效；毒副反应【摘要】 目的：对比观察重组人血管内皮抑素(恩度)联合化疗和单纯化疗治疗晚期大肠癌的临床近期疗效及毒副反应。方法：40例晚期转移性结直肠癌患者分为恩度联合化疗组（观察组）20例及单纯化疗组（对照组）20例同期对照研究，采用FOLFOX4或FOLFIRI方案化疗初治患者选用FOLFOX4方案，既往接受过奥沙利铂方案辅助化疗者选用FOLFIRI方案。观察组恩度用法:1）恩度7．5mg／，实用15mg/d，第l至14天连续给药,间歇7天重复,为1周期，化疗于恩度治疗第1天开始；：恩度7.5mg／,实用15mg/d ,第1至7天连续给药，间歇7天重复，用药14天为1周期，化疗于应用恩度第5天开始。结果：全组40例患者总体有效率为37.5% ，疾病控制率为67.5%，单纯化疗组及恩度联合化疗组有效率分别为 30%、45% ，疾病控制率分别为65%、70% ，比较无统计学差异（P0.05)。治疗毒副反应主要表现为I-II级骨髓抑制、消化道反应、肝脏毒性、心电图及凝血功能异常，III-IV级发生率低。恩度联合化疗组血液学毒性方面较单纯化疗组轻，有统计学意义（P0.05)。结论：本研究显示恩度联合化疗治疗晚期大肠癌的临床近期疗效较单纯化疗组有提高，但无统计学差异，毒副反应可耐受。[中图分类号] [文献标志码]A study on the short-term effect and toxicity of recombinant human endostatin (endostar) combination chemotherapy for advanced colorectal cancer WEN Yang1,DONG Hong-min1,WANG Wen-ling1 Department of Oncology,?Tumor?Hospital Affiliated to Guiyang Medical University，GUIZHOU 550000,China） Abstract:Objective：To compare the short-term effect and toxicity of recombinant human endostatin(endostar)based combination chemotherapy with that of general chemotherapy for advanced colorectal cancer.Methods:a total of 40 patients with advanced colorectal cancer evenly divided into two groups(endostar-based combination chemotherapy for experimental group,general chemotherapy for control group ) were treated either with FOLFOX4 or FOLFIRI regimen. Selection on chemotherapy regimen:The chemotherapy-naive patients were assigned to receive FOLFOX4 regimen.As for the ones who had had oxaliplatin adjuvant chemotherapy were treated with FOLFIRI regimen.The group for endostar-based combination chemotherapy were：:endostar 7.5mg/m2(15.0 mg/d actually),day1-day14,then repeated after 7 days.We defined this as one cycle.2):endostar:endostar 7.5mg/m2 (15.0mg/d actually),day1-day7,repeated at 7-day-interval.We defined this as one cycle.Results：Of the 40 patients,the overall efficiency rate was 37.5% and di